<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLECAINIDE <img border="0" src="../images/pr.gif"/></span><br/>(fle-kay'nide)<br/><span class="topboxtradename">Tambocor<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic, class ic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg, 150 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Local (membrane) anesthetic and antiarrhythmic with electrophysiologic properties similar to other class IC antiarrhythmic
         drugs. Slows conduction velocity throughout myocardial conduction system, increases ventricular refractoriness; little effect
         on repolarization. Prolongs His-ventricular (HQ) and QRS intervals at therapeutic doses.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Clinically, causes both hypotension and negative entropy (in higher dose ranges) and is an effective suppressant of PVCs and
         a variety of atrial and ventricular arrhythmias.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Life-threatening ventricular arrhythmias.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Atrial tachycardia and other arrhythmias unresponsive to standard agents (e.g., quinidine), Wolff-Parkinson-White syndrome,
         and recurrent ventricular tachycardias.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to flecainide; preexisting second- or third-degree AV block, right bundle branch block when associated with
         a left hemiblock unless a pacemaker is present; cardiogenic shock, significant hepatic impairment. Safety during pregnancy
         (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>CHF, sick sinus syndrome, renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Life-threatening Ventricular Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg q12h, may increase by 50 mg b.i.d. q4d (max: 400 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 13 mg/kg/d in 3 divided doses (max: 8 mg/kg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not increase dosage more frequently than every 4 d.</li>
<li>Store in tightly covered, light-resistant containers at 15°30° C (59°86° F) unless otherwise
            directed.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Dizziness,</span> headache, light-headedness, unsteadiness, paresthesias, fatigue. <span class="typehead">CV:</span> <span class="speceff-life">Arrhythmias</span>, chest pain, worsening of CHF. <span class="typehead">Special Senses:</span> <span class="speceff-common">Blurred vision, difficulty in focusing,</span> spots before eyes. <span class="typehead">GI:</span> <span class="speceff-common">Nausea,</span> constipation, change in taste perception. <span class="typehead">Body as a Whole:</span> Dyspnea, fever, edema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Cimetidine</b> may increase flecainide levels; may increase <b>digoxin</b> levels 1525%; <span class="classification">beta blockers</span> may have additive negative inotropic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted mainly in urine. <span class="typehead">Half-Life:</span> 722 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Correct preexisting hypokalemia or hyperkalemia before treatment is initiated.</li>
<li> 							Note: ECG monitoring, including Holter monitor for ambulating patients, is essential because of the possibility of drug-induced
            arrhythmias. 						
         </li>
<li>Determine pacing threshold for patients with pacemakers before initiation of therapy, after 1 wk of therapy, and at regular
            intervals thereafter.
         </li>
<li>Monitor plasma level recommended, especially in patients with severe CHF or renal failure because drug elimination may be
            delayed in these patients.
         </li>
<li> 							Note: Effective trough plasma levels are between 0.71 mcg/mL. The probability of adverse reactions increases when trough levels
            exceed 1 mcg/mL. 						
         </li>
<li>Attempt dosage reduction with caution after arrhythmia is controlled.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: It is <small>VERY</small> important to take this drug at the prescribed times. 						
         </li>
<li>Report visual disturbances to physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>